CSL's Haegarda set for Q3 launch as Shire petitions for injunction
admin 23rd June 2017 Uncategorised 0Even as it’s tangled in a rare disease patent dispute, CSL Behring has secured FDA approval for Haegarda to prevent HAE attacks in adolescents and adults. Haegarda is the first C1 esterase inhibitor for under the skin attack prevention, a method Shire says violates a patent it received back in April.
More: CSL's Haegarda set for Q3 launch as Shire petitions for injunction
Source: fierce